News J&J faces fresh litigation in UK over talc cancer risks Thousands of people in the UK have joined a lawsuit against Johnson & Johnson, claiming that it knowingly sold talc products that caused cancer.
News J&J streamlines with plan to hive off orthopaedics unit Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.
News J&J on the hook for $966m damages in latest talc lawsuit Johnson & Johnson has suffered a setback in its long-running legal defence against claims its talc products cause cancer.
News J&J claims FDA okay for bladder cancer drug TAR-200 Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.
News J&J earmarks $2bn for facility in North Carolina Johnson & Johnson has filled in some of the detail in its $55 billion investment in US facilities announced earlier this year.
News EC clears first treatment for high-risk smouldering multiple... Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.